Back |
home / stock / mgen / mgen message board
Subject | By | Source | When |
---|---|---|---|
news out!!....looks like positive meeting with FDA over | dirtydozen911 | investorshub | 08/20/2020 8:24:19 PM |
earnings and conf call wed ..5th after mkt | dirtydozen911 | investorshub | 08/04/2020 2:35:50 PM |
Quarter results on Wednesday $IMO.... | hondobud | investorshub | 08/03/2020 7:31:56 PM |
miRagens mrg-110....hits the mark in ph-1 | dirtydozen911 | investorshub | 07/28/2020 12:29:39 PM |
* * $MGEN Video Chart 07-24-2020 * * | ClayTrader | investorshub | 07/24/2020 9:14:03 PM |
that $1.85 spike on monday A H | dirtydozen911 | investorshub | 07/24/2020 1:06:47 PM |
you may want to reevaluate | whosjohngalt | investorshub | 07/24/2020 11:20:50 AM |
pr last evening was not same old | whosjohngalt | investorshub | 07/24/2020 11:04:09 AM |
why they released sane old news | Pt3 | investorshub | 07/24/2020 10:49:45 AM |
$MGEN $MGEN Analyst Research.... | hondobud | investorshub | 07/24/2020 3:01:54 AM |
Ill be filling that soon. It may not | AW104 | investorshub | 07/24/2020 12:16:49 AM |
Talk about chasing a stock...$SMH Do your TA!! | 420man | investorshub | 07/23/2020 11:14:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Miragen Therapeutics Inc. Website:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...